In a recent decision, the U.S. District Court for the District of Delaware ruled that Agilent Technologies, Inc. cannot claim damages for alleged patent infringement by Axion BioSystems, Inc. prior to the filing of its lawsuit. This ruling significantly limits the potential financial recovery for Agilent in this case.
Agilent initiated the lawsuit on February 23, 2023, alleging that Axion’s CytoView-Z 96-well plates infringed upon its U.S. Patent Nos. 7,192,752 and 7,468,255. The court’s decision to deny pre-suit damages is based on the principle that a patent holder must provide adequate notice to an alleged infringer before seeking damages for infringement. In this instance, the court determined that Agilent failed to meet the statutory requirements for such notice prior to filing the lawsuit.
Axion has consistently denied the allegations, asserting that its products do not infringe upon Agilent’s patents and that the patents in question are invalid. The company has expressed confidence in its legal position and anticipates a favorable outcome in court. Axion’s official statement on the matter can be found on their website.
This case underscores the critical importance of adhering to procedural requirements in patent litigation, particularly concerning the provision of notice to alleged infringers. The court’s ruling serves as a reminder that failure to comply with these requirements can substantially impact the scope of potential damages recoverable in such disputes.